Thomas Story & Son LLC Has $12.01 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Thomas Story & Son LLC cut its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 5.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 70,223 shares of the company’s stock after selling 4,345 shares during the period. Johnson & Johnson makes up about 4.7% of Thomas Story & Son LLC’s portfolio, making the stock its 6th biggest holding. Thomas Story & Son LLC’s holdings in Johnson & Johnson were worth $12,013,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Biondo Investment Advisors LLC boosted its stake in Johnson & Johnson by 1.8% during the third quarter. Biondo Investment Advisors LLC now owns 44,161 shares of the company’s stock valued at $7,178,000 after buying an additional 785 shares during the last quarter. Marathon Capital Management raised its position in Johnson & Johnson by 4.6% during the third quarter. Marathon Capital Management now owns 27,264 shares of the company’s stock valued at $4,404,000 after purchasing an additional 1,200 shares during the period. Castle Rock Wealth Management LLC raised its position in Johnson & Johnson by 3.9% during the fourth quarter. Castle Rock Wealth Management LLC now owns 12,855 shares of the company’s stock valued at $2,119,000 after purchasing an additional 479 shares during the period. Blueshift Asset Management LLC raised its position in Johnson & Johnson by 671.9% during the third quarter. Blueshift Asset Management LLC now owns 30,365 shares of the company’s stock valued at $4,904,000 after purchasing an additional 26,431 shares during the period. Finally, Pallas Capital Advisors LLC raised its position in Johnson & Johnson by 42.1% during the third quarter. Pallas Capital Advisors LLC now owns 68,839 shares of the company’s stock valued at $11,363,000 after purchasing an additional 20,404 shares during the period. 67.84% of the stock is owned by institutional investors.

Several research analysts recently issued reports on the company. The Goldman Sachs Group increased their price objective on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 12th. Raymond James increased their target price on Johnson & Johnson from $185.00 to $195.00 and gave the company an “outperform” rating in a research report on Thursday, April 14th. StockNews.com initiated coverage on Johnson & Johnson in a research report on Thursday, March 31st. They set a “strong-buy” rating on the stock. Sanford C. Bernstein cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and increased their target price for the company from $180.00 to $183.00 in a research report on Wednesday, March 16th. Finally, Morgan Stanley dropped their target price on Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 6th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $184.57.

Shares of Johnson & Johnson stock opened at $177.66 on Tuesday. The stock has a market cap of $467.12 billion, a P/E ratio of 22.75, a P/E/G ratio of 2.71 and a beta of 0.72. The stock’s 50 day simple moving average is $172.50 and its 200-day simple moving average is $168.01. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $184.20. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.35 and a quick ratio of 1.12.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its earnings results on Tuesday, April 19th. The company reported $2.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.61 by $0.06. The business had revenue of $23.43 billion for the quarter, compared to analysts’ expectations of $23.62 billion. Johnson & Johnson had a return on equity of 37.46% and a net margin of 22.26%. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.59 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.48 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th will be given a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a dividend yield of 2.54%. The ex-dividend date of this dividend is Monday, May 23rd. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.06. Johnson & Johnson’s payout ratio is presently 54.29%.

In other news, VP Thibaut Mongon sold 23,681 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, March 17th. The shares were sold at an average price of $176.25, for a total transaction of $4,173,776.25. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.35% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile (Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.